Regan, Meredith M.
Harvard Medical School,
United States
2025 Rank: 95994
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Urology & Nephrology
Rank in SubField 1: 3717 out of 355674 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 95994 | 97754 |
| Total Cites | 30041 | 34140 |
| H-index | 82 | 89 |
| Hm-index | 19 | 20 |
| Number of Single Authored Papers | 5 | 5 |
| Total Cites to Single Authored Papers | 6 | 6 |
| Number of Single+First Authored Papers | 28 | 28 |
| Total Cites to Single+First Authored Papers | 1338 | 1596 |
| Number of Single+First+Last Authored Papers | 51 | 51 |
| Total Cites to Single+First+Last Authored Papers | 2555 | 2953 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 24233 | 26476 |
| Ratio of Total Citations to Distinct Citing Papers | 1.24 | 1.29 |
| Self-Citation Percentage |
12.01%
|
|
Regan, Meredith M.
Dana-Farber Cancer Institute,
United States
2024 Rank: 95593
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Urology & Nephrology
Rank in SubField 1: 3747 out of 334837 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 95593 | 97019 |
| Total Cites | 28068 | 31996 |
| H-index | 78 | 86 |
| Hm-index | 18 | 19 |
| Number of Single Authored Papers | 5 | 5 |
| Total Cites to Single Authored Papers | 6 | 6 |
| Number of Single+First Authored Papers | 28 | 28 |
| Total Cites to Single+First Authored Papers | 1257 | 1489 |
| Number of Single+First+Last Authored Papers | 47 | 47 |
| Total Cites to Single+First+Last Authored Papers | 2300 | 2639 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 22738 | 24917 |
| Ratio of Total Citations to Distinct Citing Papers | 1.23 | 1.28 |
| Self-Citation Percentage |
12.28%
|
|
Regan, Meredith M.
Harvard Medical School,
United States
2023 Rank: 105922
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Urology & Nephrology
Rank in SubField 1: 4144 out of 312644 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 105922 | 109753 |
| Total Cites | 22373 | 25428 |
| H-index | 72 | 77 |
| Hm-index | 17 | 19 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 5 | 5 |
| Number of Single+First Authored Papers | 23 | 23 |
| Total Cites to Single+First Authored Papers | 1157 | 1363 |
| Number of Single+First+Last Authored Papers | 36 | 36 |
| Total Cites to Single+First+Last Authored Papers | 1918 | 2193 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 18638 | 20447 |
| Ratio of Total Citations to Distinct Citing Papers | 1.20 | 1.24 |
| Self-Citation Percentage |
12.01%
|
|
Regan, Meredith M.
Dana-Farber Cancer Institute,
2021 Rank: 110332
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Urology & Nephrology
Rank in SubField 1: 4325 out of 271773 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 110332 | 115433 |
| Total Cites | 20205 | 23236 |
| H-index | 68 | 71 |
| Hm-index | 17 | 18 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 3 | 3 |
| Number of Single+First Authored Papers | 23 | 23 |
| Total Cites to Single+First Authored Papers | 993 | 1186 |
| Number of Single+First+Last Authored Papers | 38 | 38 |
| Total Cites to Single+First+Last Authored Papers | 1554 | 1798 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 16656 | 18391 |
| Ratio of Total Citations to Distinct Citing Papers | 1.21 | 1.26 |
| Self-Citation Percentage |
13.04%
|
|